Compare Aegon Ltd. (AEG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs Vertex Pharmaceuticals Incorporated — how do they compare? Aegon Ltd. trades at $9.4 (market cap $14.16B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.4× Aegon Ltd.'s market cap, and Aegon Ltd. pays a 4.9% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| AEG | VRTX | |
|---|---|---|
Market Cap | $14.16B | $132.79B |
Sector | Financials | Health |
52-Week High | $9.53 | $529.65 |
52-Week Low | $6.79 | $376.62 |
Enterprise Value | $15.31B | $126.92B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.53, up 0.74% on the day, with a bullish technical signal driven by moving averages. The company reported revenue of $19.52 billion in 2024 with a net income margin of 3.64%, and recent earnings show mixed results with beats in Q2 and Q3 2025 but a miss in Q4. A dividend of $0.25 is scheduled for July 2026. The balance sheet shows total assets of $327.39 billion and a debt-to-asset ratio improving to 1.46 in 2024.
The outlook is cautiously optimistic with a P/E of 13.74 and P/S of 0.58 suggesting reasonable valuation, but risks include volatile cash flows and competitive pressures. Analyst sentiment is mixed with 27.78% buy ratings, highlighting potential for growth amid execution challenges.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
